Search results

Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.

Result type

Technology appraisal guidance

Published

5 January 2022

Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

Result type

Technology appraisal guidance

Published

5 November 2025